Neuroendocrine Tumor Treatment Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others), By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

March 2023 | 117 pages | ID: NEF1A600278FEN
TechSci Research

Abstracts

Global neuroendocrine tumor treatment market is anticipated to escalate in the forecast period, 2024-2028. This can be attributed to the rising prevalence of neuroendocrine tumors across the globe. The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022, titled “Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)”. Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market's growth.

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF ?, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years. This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market. Furthermore, there has been a severe betterment in the survival rates of all neuroendocrine tumor treatments, according to a study published in the JAMA Oncology Journal in 2017.

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021. Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million. Moreover, for the project 'Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial,' Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Steps were taken by the Companies

Plenty of players in the industry are also adopting strategies, for example, partnerships and collaborations, novel product launches, agreements related to distribution along with a regional extension to establish their market position. For example, Boehringer Ingelheim GmbH declared an investment of USD 270 million for the construction of a new Biologicals Development Center (BDC) that will be specializing in immunology as well as immune-oncology in June 2018. Additionally, Novartis AG, in January 2018 announced to buy of all the ordinary shares from its subsidiary group Novartis Groupe France S.A., also inclusive of Advanced Accelerator Applications S.A. (AAA).

Recent Developments

• Aerium Therapeutics Inc began operations in June 2022 with USD26.50 million (EUR 25 million) funding for systemic targeted radiation therapy and the diagnosis of low- and high-grade neuroendocrine tumors.
• Ipsen SA invested in a brand-new, cutting-edge electronic autoinjector in March 2022 for Somatuline Autogel/Somatuline Depot (lanreotide) to advance innovation in the category and enhance patient administration and injection experiences. The autoinjector is intended to enhance the patient experience for those dealing with carcinoid syndrome, acromegaly, or gastroenteropancreatic neuroendocrine tumors.
• Belzutifan (Welireg), a hypoxia-inducible factor inhibitor suitable for adults suffering from von Hippel-Lindau disease received approval from FDA in August 2021.

Market Segmentation

Global neuroendocrine tumor treatment market is segmented based on a product analysis, site analysis, end user, region, and company. Based on a product analysis, the market can be categorized into somatostatin analogs (SSA), targeted therapy, and others. Based on site analysis, the market can be divided into lungs, pancreas, colon, small intestine, and others. Based on end users, the market can be segmented into hospitals & clinics, ambulatory care centers, and others.

Company Profiles

Some of the major competitors operating in the global neuroendocrine tumor treatment market are F Hoffmann-La Roche AG, Bristol-Myers Squibb Co, Eli Lilly & Co, Novartis AG, Pfizer Inc, Amgen Inc, Exelixis Inc, Teva Pharmaceutical Industries Ltd, AVEO Pharmaceuticals Inc, and Hutchison MediPharma Ltd among others.

Report Scope:

In this report, global neuroendocrine tumor market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neuroendocrine Tumor Treatments Market, By Product Analysis:
• Somatostatin Analogs (SSA)
• Targeted Therapy
• Others
• Neuroendocrine Tumor Treatments Market, By Site Analysis:
• Lungs
• Pancreas
• Colon
• Small Intestine
• Others
• Neuroendocrine Tumor Treatments Market, By End User:
• Hospitals & Clinics
• Ambulatory Care Centers
• Others
• Neuroendocrine Tumor Treatments Market, By Region:
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• North America
• United States
• Mexico
• Canada
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global neuroendocrine Tumor treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. CLINICAL TRIAL ANALYSIS

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Site Analysis
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  6.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  6.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  6.2.4. By Region
  6.2.5. By Company (2022)
6.3. Market Map
  6.3.1. By Product Analysis
  6.3.2. By Site Analysis
  6.3.3. By End User
  6.3.4. By Region

7. ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  7.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  7.2.4. By Country
7.3. Asia-Pacific: Country Analysis
  7.3.1. China Neuroendocrine Tumor Treatment Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product Analysis
      7.3.1.2.2. By Site Analysis
      7.3.1.2.3. By End User
  7.3.2. India Neuroendocrine Tumor Treatment Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product Analysis
      7.3.2.2.2. By Site Analysis
      7.3.2.2.3. By End User
  7.3.3. Japan Neuroendocrine Tumor Treatment Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product Analysis
      7.3.3.2.2. By Site Analysis
      7.3.3.2.3. By End User
  7.3.4. South Korea Neuroendocrine Tumor Treatment Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product Analysis
      7.3.4.2.2. By Site Analysis
      7.3.4.2.3. By End User
  7.3.5. Australia Neuroendocrine Tumor Treatment Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product Analysis
      7.3.5.2.2. By Site Analysis
      7.3.5.2.3. By End User

8. EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  8.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  8.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  8.2.4. By Country
8.3. Europe: Country Analysis
  8.3.1. France Neuroendocrine Tumor Treatment Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product Analysis
      8.3.1.2.2. By Site Analysis
      8.3.1.2.3. By End User
  8.3.2. Germany Neuroendocrine Tumor Treatment Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product Analysis
      8.3.2.2.2. By Site Analysis
      8.3.2.2.3. By End User
  8.3.3. United Kingdom Neuroendocrine Tumor Treatment Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product Analysis
      8.3.3.2.2. By Site Analysis
      8.3.3.2.3. By End User
  8.3.4. Italy Neuroendocrine Tumor Treatment Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product Analysis
      8.3.4.2.2. By Site Analysis
      8.3.4.2.3. By End User
  8.3.5. Spain Neuroendocrine Tumor Treatment Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product Analysis
      8.3.5.2.2. By Site Analysis
      8.3.5.2.3. By End User

9. NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  9.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  9.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  9.2.4. By Country
9.3. North America: Country Analysis
  9.3.1. United States Neuroendocrine Tumor Treatment Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product Analysis
      9.3.1.2.2. By Site Analysis
      9.3.1.2.3. By End User
  9.3.2. Mexico Neuroendocrine Tumor Treatment Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product Analysis
      9.3.2.2.2. By Site Analysis
      9.3.2.2.3. By End User
  9.3.3. Canada Neuroendocrine Tumor Treatment Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product Analysis
      9.3.3.2.2. By Site Analysis
      9.3.3.2.3. By End User

10. SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  10.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  10.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Neuroendocrine Tumor Treatment Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product Analysis
      10.3.1.2.2. By Site Analysis
      10.3.1.2.3. By End User
  10.3.2. Argentina Neuroendocrine Tumor Treatment Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product Analysis
      10.3.2.2.2. By Site Analysis
      10.3.2.2.3. By End User
  10.3.3. Colombia Neuroendocrine Tumor Treatment Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product Analysis
      10.3.3.2.2. By Site Analysis
      10.3.3.2.3. By End User

11. MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
  11.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
  11.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  11.2.4. By Country
11.3. MEA: Country Analysis
  11.3.1. South Africa Neuroendocrine Tumor Treatment Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Product Analysis
      11.3.1.2.2. By Site Analysis
      11.3.1.2.3. By End User
  11.3.2. Saudi Arabia Neuroendocrine Tumor Treatment Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Product Analysis
      11.3.2.2.2. By Site Analysis
      11.3.2.2.3. By End User
  11.3.3. UAE Neuroendocrine Tumor Treatment Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Product Analysis
      11.3.3.2.2. By Site Analysis
      11.3.3.2.3. By End User

12. MARKET DYNAMICS

12.1. Drivers
  12.1.1. Developments and Approval of Novel Drugs
  12.1.2. Use of Artificial Intelligence (AI) in Treatment Techniques
  12.1.3. Increased Government and Company’s’ Initiatives
12.2. Challenges
  12.2.1. High Cost of the Treatment
  12.2.2. Associated Side Effects of the Treatment
  12.2.3. Stringent Regulatory Framework

13. MARKET TRENDS & DEVELOPMENTS

13.1. Upcoming Patient Assistance Programs (PAPs)
13.2. Ongoing Clinical Trials and R&D Programs
13.3. Adoption of Next-Generation Sequencing Techniques

14. COMPETITIVE LANDSCAPE

14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As Reported)
14.5. Recent Developments
14.6. SWOT Analysis
  14.6.1. F Hoffmann-La Roche AG
  14.6.2. Bristol-Myers Squibb Co
  14.6.3. Eli Lilly & Co
  14.6.4. Novartis AG
  14.6.5. Pfizer Inc
  14.6.6. Amgen Inc
  14.6.7. Exelixis Inc
  14.6.8. Teva Pharmaceutical Industries Ltd
  14.6.9. AVEO Pharmaceuticals Inc
  14.6.10. Hutchison MediPharma Ltd

15. STRATEGIC RECOMMENDATIONS